Abstract
All RAS wild-type metastatic colorectal cancer patients do not have the same benefit from the anti-epidermal growth factor receptor (EGFR) therapies. Studies have shown that nuclear factor-kB (NF-kB), hypoxia-inducible factor-1α (HIF-1α), interleukin 8 (IL-8) and transforming growth factor β (TGF-β) may be therapeutic targets for metastatic colorectal cancers. We aimed to clarify the prognostic value of NF-κB, HIF-1α, IL-8 and TGF-β expression in patients receiving EGFR inhibitors in left sided mCRC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have